American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.
What is American Oriental Bioengineering stock price today?▼
The current price of AOBI is $0 USD — it has decreased by -42.86% in the past 24 hours. Watch American Oriental Bioengineering stock price performance more closely on the chart.
What is American Oriental Bioengineering stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange American Oriental Bioengineering stocks are traded under the ticker AOBI.
What were American Oriental Bioengineering earnings last quarter?▼
AOBI earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is American Oriental Bioengineering revenue for the last year?▼
American Oriental Bioengineering revenue for the last year amounts to 145.1M USD.
What is American Oriental Bioengineering net income for the last year?▼
AOBI net income for the last year is -59.71M USD.
How many employees does American Oriental Bioengineering have?▼
As of April 21, 2026, the company has 3,719 employees.
In which sector is American Oriental Bioengineering located?▼
American Oriental Bioengineering operates in the Essentials sector.
When did American Oriental Bioengineering complete a stock split?▼
The last stock split for American Oriental Bioengineering was on April 03, 2014 with a ratio of 1:501.
Where is American Oriental Bioengineering headquartered?▼
American Oriental Bioengineering is headquartered in Beijing, United States.